Management:
The management team of Cognitive Pharmaceuticals, Ltd. consists of Wayne Hoss, Ph.D., CEO and Director of Technology Development; Edward J. (Ted) McGuire, Ph.D., President and Director of Regulatory Affairs; and William (Bill) Messer, Ph.D., Director of Research. Dr. Hoss has extensive experience in the management of research and technology. Dr. McGuire has 30 years of experience in drug development, including the submission of Lipitor®. The National Institutes of Health as well as pharmaceutical companies have funded Dr. Messer’s research on Alzheimer’s Disease during the past 15 years.
Board of Directors:
The three members of the management team and Debasis Ghosh, Ph.D., a co-founder and former President of Cognitive Pharmaceuticals, Ltd., constitute the Board of Directors. Dr. Ghosh has extensive experience in the discovery and development of medicinal agents for the treatment of brain disorders and cancer.
Scientific Advisory Board:
A Scientific Advisory Board has been established and a number of national and international experts are currently being recruited. Current members include:
- Graham Durant, Ph.D., Co-inventor of Tagamet and CDD-0102
- Paul Erhardt, Ph.D., Inventor of Esmolol, Professor, Universty of Toledo
- Chandramallika Ghosh, Ph.D., Head, In Vitro Toxicology, NAMSA
- Kenneth Bachmann, Ph.D., Distinguished Professor, University of Toledo
- John Kasckow, MD, Ph.D., Director of Geriatric Psychiatry, University of Cincinnati & Virginia
Funding:
Basic research underlying the RBDD technology was sponsored by grants, primarily to the University of Toledo, from pharmaceutical companies, the NIH, and a private foundation. Total expenditures on discovery and development thus far are in excess of $2.5 million. An additional $2.5 million will be required to complete pre-clinical toxicology studies and the manufacturing of CDD-0102, supporting an IND in 2005. The management team believes that the project has the potential for significant return on investment within a reasonable time frame.
